Hydroxychloroquine Market by Product type (Tablet and Active Pharmaceutical Ingredients), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Specialty Drug Store, and Retail Pharmacy), and Disease (Malaria, Rheumatoid Arthritis, Lupus Erythematosus, Coronavirus, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
- ALL4079329
- 246 Pages
- September 2020
- Materials and Chemicals
Hydroxychloroquine, and anti-malarial drug, when combined with chloroquine has the potential to be the major game-changer in the medical history. In certain small and vitro, uncontrolled or poorly controlled clinical studies, it demonstrated antiviral activity against (SARS–CoV-2) severe acute respiratory syndrome–coronavirus-2. Such researches are considered as hypothesis. However, followed by the tweet of President Trump, it completely changed the scenario of the market, with reports of shortages of the medicine in pharmacies within 24 hours. Amidst the outbreak, certain nations such as the U.S. and India are endorsing its use as preventive measures for COVID-19.
The growth of the global hydroxychloroquine market is drive by surge in demand for the medication, which led to hike in production of the drug by the Indian Government. IPCA Laboratories, which have approximately 70% of the market share in this sector in India, has increased its production tenfold. However, the nationwide lockdown acted as a hindrance for growth of the global market. In addition, disruption in logistic chains and less availability of raw materials, which are mostly scoured from China have restrained the market growth. With the initiation of normal operation in China after the lockdown and backward integration of some industry players have helped the market to cope up to a certain extent.
In April 2019, IPCA Laboratories signed a contract to acquire Maharashtra-based Ramdev Chemical Pvt. Ltd. According to the contract, IPCA Laboratories is supposed to buy the company, which is associated with the marketing and manufacturing of advanced drug intermediates, active pharmaceutical ingredients (APIs), custom synthesis molecules, and fine chemicals. Thus, this initiative by IPCA Laboratories will help the company in increasing the production capacity of the drug and contribute in meeting the present demand.
On March 25 2020, the Indian Government imposed a ban on export of the drug to ensure that the nation had adequate stock of the medication to meet domestic needs. However, later the government decided to lift the ban partially. The SAARC nations along with other 30 nations and the U.S. and West Asia proposed India to lift the ban on export. Considering the high demand for the medication, pharmaceutical companies in the nation have planned to increase the production by 5 to 6 times to over 70 metric tons by May 2020. Apart from IPCA Laboratories Ltd., Zydus Cadila and Wallace Pharmaceuticals are some of the other leading manufacturers of hydroxychloroquine.
The global hydroxychloroquine market is segmented into product type, distribution channel, disease, and region. On the basis of product type, the market is bifurcated into tablet and active pharmaceutical ingredients. Depending on distribution channel, the market is fragmented into hospital pharmacy, online pharmacy, specialty drug store, and retail pharmacy. The diseases covered in the study include malaria, rheumatoid arthritis, lupus erythematosus, coronavirus, and others. Region wise, the hydroxychloroquine market analysis is done across North America, Europe, Asia-Pacific, and LAMEA (Latin America, Middle East, and Africa).
The key players operating in the hydroxychloroquine market are Cadila Healthcare Ltd., Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Zydus Cadila. The companies have focused on various strategies such as new product launches, partnerships, acquisitions, and mergers for retaining their existing customer base and further increase their market share.
KEY BENEFITS FOR STAKEHOLDERS
• The report provides extensive qualitative and quantitative analysis of the current trends and future estimations of the hydroxychloroquine market from 2019 to 2027 to determine the prevailing opportunities.
• Comprehensive analysis of factors that drive and restrict hydroxychloroquine market growth is provided.
• The hydroxychloroquine market forecast and estimations are based on factors impacting the market growth, in terms of value.
• Profiles of leading players operating in the hydroxychloroquine market are provided to understand the global competitive scenario.
• The report provides extensive qualitative insights on the significant segments and regions exhibiting favorable market share.
KEY MARKET SEGMENTS
By Product type
• Tablet
• Active Pharmaceutical Ingredients
By Distribution Channel
• Hospital Pharmacy
• Online Pharmacy
• Specialty Drug Store
• Retail Pharmacy
By Disease
• Malaria
• Rheumatoid Arthritis
• Lupus Erythematosus
• Coronavirus
• Others
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA
Key Players
o Cadila Healthcare Ltd
o Hikma Pharmaceuticals PLC
o Ipca Laboratories Ltd
o Mylan N.V
o Novartis AG
o Pfizer Inc.
o Sanofi S.A.
o Taj Pharmaceuticals Ltd.
o Teva Pharmaceutical Industries Ltd.
o Torrent Pharmaceuticals Ltd
o Zydus Cadila
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Primary research
1.4.2.Secondary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top Player Positioning
3.2.3.Porter's five forces analysis
3.3.Patent Analysis
3.4.Value chain analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in demand for HCQ as potential treatment source amidst pandemic
3.5.1.2.Increase in cases of malaria
3.5.2.Restraint
3.5.2.1.Several side-effects of the medicine
3.5.2.2.Ban from several countries owing to lacking study data
3.5.2.3.Ongoing research and positive results of other drugs for potential cure
3.5.3.Opportunity
3.5.3.1.Repurposing hydroxychloroquine as anti-cancer drug
3.6.Impact of CORONA (COVID 19) outbreak on global hydroxychloroquine market
CHAPTER 4:HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Tablet
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.3.Active pharmaceutical ingredient
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
CHAPTER 5:HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospital pharmacy
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.3.Retail pharmacy
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.4.Online pharmacy
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.5.Specialty drug store
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region
CHAPTER 6:HYDROXYCHLOROQUINE MARKET, BY DISEASES
6.1.Overview
6.1.1.Market size and forecast
6.2.Malaria
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.3.Rheumatoid arthritis
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.4.Lupus Erythematosus
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.5.Coronavirus
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by region
6.6.Others
6.6.1.Key market trends, growth factors, and opportunities
6.6.2.Market size and forecast, by region
CHAPTER 7:HYDROXYCHLOROQUINE MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by product type
7.2.3.Market size and forecast, by distribution channel
7.2.4.Market size and forecast, by disease
7.2.5.Market share analysis, by country
7.2.6.U.S.
7.2.6.1.Market size and forecast, by product type
7.2.6.2.Market size and forecast, by distribution channel
7.2.6.3.Market size and forecast, by disease
7.2.7.Canada
7.2.7.1.Market size and forecast, by product type
7.2.7.2.Market size and forecast, by distribution channel
7.2.7.3.Market size and forecast, by disease
7.2.8.Mexico
7.2.8.1.Market size and forecast, by product type
7.2.8.2.Market size and forecast, by distribution channel
7.2.8.3.Market size and forecast, by disease
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by product type
7.3.3.Market size and forecast, by distribution channel
7.3.4.Market size and forecast, by disease
7.3.5.Market share analysis, by country
7.3.6.Germany
7.3.6.1.Market size and forecast, by product type
7.3.6.2.Market size and forecast, by distribution channel
7.3.6.3.Market size and forecast, by disease
7.3.7.France
7.3.7.1.Market size and forecast, by product type
7.3.7.2.Market size and forecast, by distribution channel
7.3.7.3.Market size and forecast, by disease
7.3.8.UK
7.3.8.1.Market size and forecast, by product type
7.3.8.2.Market size and forecast, by distribution channel
7.3.8.3.Market size and forecast, by disease
7.3.9.Italy
7.3.9.1.Market size and forecast, by product type
7.3.9.2.Market size and forecast, by distribution channel
7.3.9.3.Market size and forecast, by disease
7.3.10.Spain
7.3.10.1.Market size and forecast, by product type
7.3.10.2.Market size and forecast, by distribution channel
7.3.10.3.Market size and forecast, by disease
7.3.11.Rest of Europe
7.3.11.1.Market size and forecast, by product type
7.3.11.2.Market size and forecast, by distribution channel
7.3.11.3.Market size and forecast, by disease
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by product type
7.4.3.Market size and forecast, by distribution channel
7.4.4.Market size and forecast, by disease
7.4.5.Market share analysis, by country
7.4.6.China
7.4.6.1.Market size and forecast, by product type
7.4.6.2.Market size and forecast, by distribution channel
7.4.6.3.Market size and forecast, by disease
7.4.7.Japan
7.4.7.1.Market size and forecast, by product type
7.4.7.2.Market size and forecast, by distribution channel
7.4.7.3.Market size and forecast, by disease
7.4.8.India
7.4.8.1.Market size and forecast, by product type
7.4.8.2.Market size and forecast, by distribution channel
7.4.8.3.Market size and forecast, by disease
7.4.9.Australia
7.4.9.1.Market size and forecast, by product type
7.4.9.2.Market size and forecast, by distribution channel
7.4.9.3.Market size and forecast, by disease
7.4.10.South Korea
7.4.10.1.Market size and forecast, by product type
7.4.10.2.Market size and forecast, by distribution channel
7.4.10.3.Market size and forecast, by disease
7.4.11.Rest of Asia-Pacific
7.4.11.1.Market size and forecast, by product type
7.4.11.2.Market size and forecast, by distribution channel
7.4.11.3.Market size and forecast, by disease
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by product type
7.5.3.Market size and forecast, by distribution channel
7.5.4.Market size and forecast, by disease
7.5.5.Market share analysis, by country
7.5.6.Brazil
7.5.6.1.Market size and forecast, by product type
7.5.6.2.Market size and forecast, by distribution channel
7.5.6.3.Market size and forecast, by disease
7.5.7.Saudi Arabia
7.5.7.1.Market size and forecast, by product type
7.5.7.2.Market size and forecast, by distribution channel
7.5.7.3.Market size and forecast, by disease
7.5.8.South Africa
7.5.8.1.Market size and forecast, by product type
7.5.8.2.Market size and forecast, by distribution channel
7.5.8.3.Market size and forecast, by disease
7.5.9.Rest of LAMEA
7.5.9.1.Market size and forecast, by product type
7.5.9.2.Market size and forecast, by distribution channel
7.5.9.3.Market size and forecast, by disease
CHAPTER 8:COMPANY PROFILES:
8.1.Cadila Healthcare Limited
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio
8.1.4.Business performance
8.2.Hikma Pharmaceuticals PLC
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio
8.2.4.Business performance
8.3.IPCA Laboratories Ltd.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Product portfolio
8.3.4.Business performance
8.3.5.Key Developmental strategies
8.4.Mylan N.V.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance
8.4.5.Key Developmental strategies
8.5.Novartis International AG
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.Pfizer Inc.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Product portfolio
8.6.4.Business performance
8.7.Sanofi S.A.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Product portfolio
8.7.4.Business performance
8.8.Taj Pharma Group
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Product portfolio
8.9.Teva Pharmaceutical Industries Ltd.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Product portfolio
8.9.4.Business performance
8.10.Torrent Pharmaceuticals Limited
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Business performance
TABLE 01.GLOBAL HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 02.HYDROXYCHLOROQUINE MARKET FOR TABLET, BY REGION, 2019–2027 ($MILLION)
TABLE 03.HYDROXYCHLOROQUINE MARKET FOR ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2019–2027 ($MILLION)
TABLE 04.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 05.HYDROXYCHLOROQUINE MARKET FOR HOSPITAL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 06.HYDROXYCHLOROQUINE MARKET FOR RETAIL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 07.HYDROXYCHLOROQUINE MARKET FOR ONLINE PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 08.HYDROXYCHLOROQUINE MARKET FOR SPECIALTY DRUG STORE, BY REGION, 2019–2027 ($MILLION)
TABLE 09.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISEASES, 2019–2027 ($MILLION)
TABLE 10.HYDROXYCHLOROQUINE MARKET FOR MALARIA, BY REGION, 2019–2027 ($MILLION)
TABLE 11.HYDROXYCHLOROQUINE MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2019–2027 ($MILLION)
TABLE 12.HYDROXYCHLOROQUINE MARKET FOR LUPUS ERYTHEMATOSUS, BY REGION, 2019–2027 ($MILLION)
TABLE 13.HYDROXYCHLOROQUINE MARKET FOR CORONAVIRUS, BY REGION, 2019–2027 ($MILLION)
TABLE 14.HYDROXYCHLOROQUINE MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 15.HYDROXYCHLOROQUINE MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 16.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 17.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 18.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 19.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 20.U.S. HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 21.U.S. HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 22.U.S. HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 23.CANADA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 24.CANADA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 25.CANADA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 26.MEXICO HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 27.MEXICO HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 28.MEXICO HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 29.EUROPE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 30.EUROPE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 31.EUROPE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 32.EUROPE HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 33.GERMANY HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 34.GERMANY HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 35.GERMANY HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 36.FRANCE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 37.FRANCE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 38.FRANCE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 39.UK HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 40.UK HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 41.UK HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 42.ITALY HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 43.ITALY HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 44.ITALY HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 45.SPAIN HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 46.SPAIN HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 47.SPAIN HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 48.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 49.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 50.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 51.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 52.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 53.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 54.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 55.CHINA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 56.CHINA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 57.CHINA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 58.JAPAN HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 59.JAPAN HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 60.JAPAN HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 61.INDIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 62.INDIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 63.INDIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 64.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 65.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 66.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 67.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 68.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 69.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 73.LAMEA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 74.LAMEA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 75.LAMEA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 76.LAMEA HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 77.BRAZIL HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 78.BRAZIL HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 79.BRAZIL HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 80.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 81.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 82.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 83.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 84.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 85.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 86.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 87.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 88.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019–2027 ($MILLION)
TABLE 89.ZYDUS CADILA: COMPANY SNAPSHOT
TABLE 90.ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 91.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 92.HIKMA: COMPANY SNAPSHOT
TABLE 93.HIKMA: PRODUCT PORTFOLIO
TABLE 94.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 95.IPCA: COMPANY SNAPSHOT
TABLE 96.IPCA: PRODUCT PORTFOLIO
TABLE 97.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 98.IPCA: PRODUCT PORTFOLIO
TABLE 99.MYLAN: COMPANY SNAPSHOT
TABLE 100.MYLAN: PRODUCT PORTFOLIO
TABLE 101.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 102.MYLAN: PRODUCT PORTFOLIO
TABLE 103.NOVARTIS: COMPANY SNAPSHOT
TABLE 104.NOVARTIS: OPERATING SEGMENTS
TABLE 105.NOVARTIS: PRODUCT PORTFOLIO
TABLE 106.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 107.PFIZER INC.: COMPANY SNAPSHOT
TABLE 108.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 109.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 110.SANOFI: COMPANY SNAPSHOT
TABLE 111.SANOFI: PRODUCT PORTFOLIO
TABLE 112.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 113.TAJ: COMPANY SNAPSHOT
TABLE 114.TAJ: PRODUCT PORTFOLIO
TABLE 115.TEVA: COMPANY SNAPSHOT
TABLE 116.TEVA: PRODUCT PORTFOLIO
TABLE 117.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 118.TORRENT: COMPANY SNAPSHOT
TABLE 119.TORRENT: PRODUCT PORTFOLIO
TABLE 120.OVERALL FINANCIAL STATUS ($MILLION)
Similar Reports
Photonic Crystals are attractive optical materials for controlling and manipulating the flow of light. The global market for components and modules using Photonic Crystals indicates a CAGR of 33.1% and is estimated to reach $20.4 billion in 2017.
Nanomaterials possess nanoscale dimensions ranging from 1 to 100 nanometers. They occur naturally or can be engineered with specific properties such as size, shape, surface, and chemistry. Volcanic ash and forest fibers are some of the examples of natural nano...
- Publish Date: September 10, 2016
- $5820
Global molded plastics market was valued at $529,845 million in 2016, and is expected to garner $690,158 million by 2023, registering a CAGR of 3.9% from 2017 to 2023. Molded plastics are synthetically produced non-metallic compounds, which can be molded ...
- Publish Date: July 4, 2017
- $5370
